Illumina (NASDAQ:ILMN) Given Overweight Rating at Stephens

Stephens reiterated their overweight rating on shares of Illumina (NASDAQ:ILMN) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $170.00 price target on the life sciences company’s stock.

Several other research analysts have also commented on ILMN. HSBC cut Illumina from a buy rating to a hold rating in a research note on Tuesday, January 16th. OTR Global restated a mixed rating on shares of Illumina in a report on Wednesday, March 20th. Scotiabank lowered their price target on Illumina from $185.00 to $176.00 and set a sector outperform rating for the company in a research report on Monday. Robert W. Baird boosted their price objective on shares of Illumina from $125.00 to $128.00 and gave the company a neutral rating in a research report on Friday, May 3rd. Finally, StockNews.com lowered shares of Illumina from a buy rating to a hold rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Illumina presently has an average rating of Hold and an average price target of $164.65.

Illumina Stock Down 5.2 %

Shares of ILMN opened at $112.82 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market capitalization of $17.97 billion, a price-to-earnings ratio of -13.84 and a beta of 1.20. Illumina has a 1 year low of $89.00 and a 1 year high of $213.91. The business’s 50 day simple moving average is $129.13 and its 200-day simple moving average is $126.95.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the firm earned $0.08 earnings per share. Illumina’s revenue was down 1.0% on a year-over-year basis. As a group, equities analysts expect that Illumina will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.17% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently made changes to their positions in the stock. Bouvel Investment Partners LLC raised its holdings in Illumina by 1.3% in the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after purchasing an additional 84 shares in the last quarter. STF Management LP raised its stake in shares of Illumina by 3.5% during the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 90 shares in the last quarter. Global Retirement Partners LLC lifted its position in Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after acquiring an additional 94 shares during the last quarter. Gulf International Bank UK Ltd boosted its stake in Illumina by 0.7% in the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after acquiring an additional 98 shares in the last quarter. Finally, Clear Creek Financial Management LLC boosted its stake in Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after acquiring an additional 100 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.